• Abstract Title: Transforming Anabolic Treatments for Osteoporosis: New Clinical Data Supports a Single EB613 Tablet [Oral PTH(1-34)] as the Final Candidate for a Phase 3 Study
    Session Title: Late-Breaking Oral Abstract/Rapid-Fire II
    Session Date/Time: Sunday, June 14, 2026, 3:30 – 4:15 PM CT
  • Abstract Title: Pre-Clinical Results for EB612: First-in-Class Oral Long-Acting PTH(1-34) Analog as Hormone Replacement Tablet for Patients with Hypoparathyroidism
    Session Date/Time: Monday, June 15, 2026, 12:00 – 1:30 PM CT
  • Abstract Title: EB618, First-in-Class Oral Tablet of Dual GLP-1/Glucagon Receptor Agonist for Patients with Obesity and Metabolic Disorders: Results from PK-PD Study in Non-Human Primates

    Session Date/Time: Saturday, June 13, 2026, 12:15 – 1:45 PM CT